EUROPEAN BIOMANUFACTURING SUMMIT in Berlin
From today, May 31st, to June 1st, the European Biomanufacturing Summit is taking place in Berlin, Germany. This event brings together key department representatives from global companies such as Bayer, AstraZeneca, Boehringer Ingelheim, Ipsen, Amgen, Abbie, and others to discuss and collaborate on biosimilars and biopharmaceuticals with a focus on Europe, following a previous event held in the United States.
The Global Sales Team at Prestige Biologics is sensing a vibrant market atmosphere in Europe that is becoming more active than before. With the end of the COVID-19 pandemic, many global pharmaceutical companies are now engaging in discussions about stable supply chains for the development, production, and distribution of new stages of biopharmaceuticals. Both the U.S. and European biopharmaceutical markets are actively preparing for a new future.
Various global companies are concerned about rapid production expansion of pharmaceuticals and actively exploring potential CDMO partners who can flexibly respond to these demands. In contrast to 2022, the biopharmaceutical market in 2023 is undergoing significant changes. Instead of previous expansion strategies involving M&A or direct facility expansion, companies are now more meaningfully evaluating collaborations and partnerships with diverse entities.
By leveraging customer-centric facilities and technical service capabilities, Prestige Biologics is expanding touchpoints with potential future customers and deepening relationships.(Prestige Biologics Global Sales Division, Berlin)
Prestige Biologics has secured a significant track record over the past few years. It has sufficiently demonstrated its production capabilities for monoclonal antibody biosimilars through its pipeline, such as HD201 and HD204, and has simultaneously proven its capabilities in the development and production of novel antibodies. Additionally, Prestige Biologics' Alita Smart BioFactory, a technological model for bioprocessing, is being recognized for its practical application and improvements in productivity and efficiency.
The Alita Smart BioFactory technology from Prestige Biologics is an advanced technological model. It facilitates the rapid market launch of customer products. Particularly, it explains the ability to scale up to 2,000 liters and then scale out by connecting 2,000L single-use bioreactors, providing ideal flexibility to meet evolving customer demands. European customers also understand the challenges of responding to diverse demands with fixed stainless-steel bioreactors larger than 10,000 liters. Therefore, the validated production capacity of Prestige Biologics, which rapidly expands production capacity with a focus on 2,000L single-use bioreactors, is gaining more attention. Global companies are expected to show interest in Prestige Biologics' choices and focus, which consider potential future diversification of customer demands as important decisions, not just changes in technology.
During the first half of 2023, Prestige Biologics has increased its interactions with potential customers by several times compared to the previous year. Extending these efforts, it is preparing a dedicated booth and participating in the BIO USA event to be held in Boston from June 5th to June 8th.
Prestige Biopharma plans to introduce its pipeline held by the group and discover possibilities for deeper collaborations. It also plans to expand touchpoints with global customers and pursue partnerships that foster deeper relationships.
With its accumulated process technology development capabilities, experience and technical expertise in improving production efficiency, and the ability to support efficient collaboration with customers, Prestige Biologics aims to be a unique partner that leads customers' major pipelines to commercial production.
Prestige Biologics strives to earn trust from customers as an extension of their team, contributing to human life and growing as a pivotal entity.